Retinoyl beta-glucuronide: a biologically active interesting retinoid

Area of Science:

• Dermatology and Oncology
• Retinoid Pharmacology
• Toxicology and Pharmacokinetics

Background:

• All-trans-retinoic acid (RA) is a biologically active retinoid with therapeutic applications.
• RA exhibits significant toxic side effects, limiting its clinical utility.
• All-trans retinoyl beta-glucuronide (RAG) has demonstrated similar biological activity to RA.

Purpose of the Study:

• To evaluate all-trans retinoyl beta-glucuronide (RAG) as a potential non-toxic substitute for all-trans-retinoic acid (RA).
• To assess the toxicity, pharmacokinetics, and efficacy of RAG in preclinical models.
• To determine the safety and effectiveness of RAG for clinical applications.

Main Methods:

• Subcutaneous injection of graded doses of RA and RAG into pregnant rats.
• Topical application of RAG and RA to swine dorsal skin, followed by histological analysis.
• Chronic administration of RAG to mice to assess pharmacokinetics.
• Evaluation of RAG's effect on neuroblastoma tumor development and growth in nude mice.

Main Results:

• RAG exhibited significantly lower toxicity than RA in both pregnant rats and swine models.
• Chronic RAG administration in mice achieved sustained blood levels of the parent retinoid.
• RAG demonstrated comparable antitumor effects to RA in neuroblastoma models, but without significant adverse side effects.

Conclusions:

• All-trans retinoyl beta-glucuronide (RAG) functions as a safe and effective alternative to all-trans-retinoic acid (RA).
• RAG offers a reduced toxicity profile compared to RA, enhancing its potential for clinical use.
• Preclinical data support RAG's utility in various therapeutic settings where retinoids are indicated.